June 14, 2012Open Access

Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

Key Points

Key points are not available for this paper at this time.

Abstract

Trametinib, as compared with chemotherapy, improved rates of progression-free and overall survival among patients who had metastatic melanoma with a BRAF V600E or V600K mutation. (Funded by GlaxoSmithKline; METRIC ClinicalTrials.gov number, NCT01245062.).

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Cite this study

Flaherty et al. (Thu,) studied this question.

www.synapsesocial.com/papers/69d97f6ac7f0c3ae80a3dbb9 — DOI: https://doi.org/10.1056/nejmoa1203421

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Mutations of the BRAF gene in human cancer· 2002 · 10,652 citations
Embryonic stem‐cell‐preconditioned microenvironment induces loss of cancer cell properties in human melanoma cells· 2011 · 25 citations
Adjuvant Interferon Therapy for Patients at High Risk for Recurrent Melanoma: An Updated Systematic Review and Practice Guideline· 2012 · 54 citations
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)· 2008 · 29,240 citations

Authors

Keith T. Flaherty

Caroline Robert

Peter Hersey

Journals

New England Journal of Medicine

Actions

Institutions

Massachusetts General Hospital

Inserm

Heidelberg University

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Cite this study

Also consider

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion